AR061629A1 - Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas - Google Patents
Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticasInfo
- Publication number
- AR061629A1 AR061629A1 ARP070102807A ARP070102807A AR061629A1 AR 061629 A1 AR061629 A1 AR 061629A1 AR P070102807 A ARP070102807 A AR P070102807A AR P070102807 A ARP070102807 A AR P070102807A AR 061629 A1 AR061629 A1 AR 061629A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- heteroaryl
- aryl
- cycloalkyl
- heterocycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composiciones farmacéuticas que comprenden los compuestos anteriormente mencionados para administrar a un sujeto que sufre de una infeccion por HCV, y métodos de tratar una infeccion por HCV en un sujeto administrando una composicion farmacéutica que comprende los compuestos de la presente. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula 1; así como sus sales aceptables para uso farmacéutico, ésteres y prodrogas, en donde: A se selecciona entre H, -(C=O)-O-R1, - (C=O)-R2, -C(=O)-NH-R2, o - S(O)-R1, -S(O)2NHR2; cada R1se selecciona en forma independiente entre el grupo formado por: arilo; arilo sustituido; heteroarilo; heteroarilo sustituido; heterocicloalquilo o heterocicloalquilo sustituido; alquilo C1-8, alquenilo C2-8, o alquinilo C2-8 cada uno con 0, 1, 2, o 3 heteroátomos seleccionados entre O, S, o N; alquilo C1-8 sustituido, alquenilo C2-8 sustituido, o alquinilo C2-8 sustituido cada uno con 0, 1, 2, o 3 heteroátomos seleccionados entre O, S o N; cicloalquilo C3-12, o cicloalquilo C3-12 sustituido; cicloalquenilo C3-12, o cicloalquenilo C3-12 sustituido; cada R2 se selecciona en forma independiente entre el grupo formado por: hidrogeno; arilo; arilo sustituido; heteroarilo; heteroarilo sustituido; heterocicloalquilo o heterocicloalquilo sustituido; alquilo C1-8, alquenilo C2-8, o alquinilo C2-8 cada uno con 0, 1, 2, o 3 heteroátomos seleccionados entre O, S, o N; alquilo C1-8 sustituido, alquenilo C2-8 sustituido, o alquinilo C2-8 sustituido cada uno con 0, 1, 2, o 3 heteroátomos seleccionados entre O, S o N; cicloalquilo C3-12, o cicloalquilo C3-12 sustituido; cicloalquenilo C3-12, o cicloalquenilo C3-12 sustituido; G se selecciona entre -NHS(O)2-R3 o -NH(SO2)NR4R5; donde cada R3 se selecciona en forma independiente entre: arilo; arilo sustituido; heteroarilo; heteroarilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido; y alquilo C1-8, alquenilo C2-8, o alquinilo C2-8 cada uno con 0, 1, 2, o 3 heteroátomos seleccionados entre O, S, o N; alquilo C1-8 sustituido, alquenilo C2-8 sustituido, o alquinilo C2-8 sustituido cada uno con 0, 1, 2, o 3 heteroátomos seleccionados entre O, S o N; cicloalquilo C3-12, o cicloalquilo C3-12 sustituido; cicloalquenilo C3-12, o cicloalquenilo C3-12 sustituido; con la salvedad de que R3 no sea -CH2Ph ni -CH2CH2Ph; cada R4 y R5 se seleccionan en forma independiente entre: hidrogeno; arilo; arilo sustituido; heteroarilo; heteroarilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido; y alquilo C1-8, alquenilo C2-8, o alquinilo C2-8 cada uno con 0, 1, 2, o 3 heteroátomos seleccionados entre O, S, o N; alquilo C1-8 sustituido, alquenilo C2-8 sustituido, o alquinilo C2-8 sustituido cada uno con 0, 1, 2, o 3 heteroátomos seleccionados entre O, S o N; cicloalquilo C3-12, o cicloalquilo C3-12 sustituido; cicloalquenilo C3-12, o cicloalquenilo C3-12 sustituido; L se selecciona entre -CH2-, -O-, -S-, o -S(O)2-; X y Y tomados junto con los átomos de carbono a los cuales están unidos forman una porcion cíclica seleccionada entre arilo, arilo sustituido, heteroarilo, o heteroarilo sustituido: W está ausente o se selecciona entre -O-, -S-, -NH-, -N(Me)-, -C(O)NH-, o -C(O)N(Me)-; como alternativa, W puede ser alquileno C2-4, alquileno C2-4 sustituido; Z se selecciona entre los grupos formados por: hidrogeno; -CN; N3, halogeno; -NH-N=CH(R2), donde R2 tiene los valores que se han definido; arilo, arilo sustituido; heteroarilo, heteroarilo sustituido; cicloalquilo C3-12, cicloalquilo C3-12 sustituido, heterocicloalquilo, heterocicloalquilo sustituido; alquilo C1-6 con 0, 1, 2, o 3 heteroátomos seleccionados entre O, S, o N, opcionalmente sustituido con uno o más sustituyentes seleccionados entre halogeno, arilo, arilo sustituido, heteroarilo, o heteroarilo sustituido; alquenilo C2-6 con 0, 1, 2, o 3 heteroátomos seleccionados entre O, S, o N, opcionalmente sustituido con uno o más sustituyentes seleccionados entre halogeno, arilo, arilo sustituido, heteroarilo, o heteroarilo sustituido; alquinilo C2-6 con 0, 1, 2, o 3 heteroátomos seleccionados entre O, S, o N, opcionalmente sustituido con uno o más sustituyentes seleccionados entre halogeno, arilo, arilo sustituido, heteroarilo, o heteroarilo sustituido; j = 0, 1, 2, 3, o 4; k =1, 2, o 3; m = 0, 1, o 2; y ----- denota un enlace simple o doble carbono-carbono.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87244206P | 2006-06-26 | 2006-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061629A1 true AR061629A1 (es) | 2008-09-10 |
Family
ID=38846474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102807A AR061629A1 (es) | 2006-06-26 | 2007-06-25 | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8809264B2 (es) |
| EP (1) | EP2066326A4 (es) |
| JP (1) | JP5520046B2 (es) |
| KR (1) | KR101505056B1 (es) |
| CN (1) | CN101478970B (es) |
| AR (1) | AR061629A1 (es) |
| AU (1) | AU2007265157B2 (es) |
| BR (1) | BRPI0714074A2 (es) |
| CA (1) | CA2654945C (es) |
| IL (1) | IL195512A (es) |
| MX (1) | MX2008016528A (es) |
| NZ (1) | NZ573275A (es) |
| PE (1) | PE20080992A1 (es) |
| RU (1) | RU2475494C2 (es) |
| TW (1) | TWI454264B (es) |
| UY (1) | UY30437A1 (es) |
| WO (1) | WO2008002924A2 (es) |
| ZA (1) | ZA200810519B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US20090148407A1 (en) | 2005-07-25 | 2009-06-11 | Intermune, Inc. | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication |
| ATE493409T1 (de) | 2005-10-11 | 2011-01-15 | Intermune Inc | Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| KR101615500B1 (ko) | 2006-10-27 | 2016-04-27 | 머크 샤프 앤드 돔 코포레이션 | Ｈｃｖ ｎｓ3 프로테아제 억제제 |
| EP2185524A1 (en) | 2007-05-10 | 2010-05-19 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
| AR067180A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Compuestos antivirales |
| CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| WO2009073713A1 (en) * | 2007-12-05 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Oximyl macrocyclic derivatives |
| CA2708042A1 (en) * | 2007-12-05 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl derivatives |
| US8193346B2 (en) * | 2007-12-06 | 2012-06-05 | Enanta Pharmaceuticals, Inc. | Process for making macrocyclic oximyl hepatitis C protease inhibitors |
| MX2010008109A (es) * | 2008-01-24 | 2010-09-22 | Enanta Pharm Inc | Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv). |
| AU2009210789B2 (en) | 2008-02-04 | 2014-01-30 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| CA2705300A1 (fr) * | 2008-02-15 | 2009-06-04 | Xeda International | Macrocyclic inhibitors of hepatitis c protease |
| US8372802B2 (en) * | 2008-03-20 | 2013-02-12 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors |
| AP2010005416A0 (en) | 2008-04-15 | 2010-10-31 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication. |
| ES2491090T3 (es) | 2008-07-22 | 2014-09-05 | Merck Sharp & Dohme Corp. | Combinaciones de un compuesto de quinoxalina macrocíclica que es un inhibidor de la proteasa NS3 del VHC con otros agentes del VHC |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| US8936781B2 (en) | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| TW201117812A (en) | 2009-08-05 | 2011-06-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| SI2477980T1 (sl) | 2009-09-15 | 2017-01-31 | Taigen Biotechnology Co., Ltd. | Inhibitorji HCV proteaze |
| WO2011049908A2 (en) * | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
| JP2013511562A (ja) * | 2009-11-24 | 2013-04-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎阻害化合物 |
| JP5717768B2 (ja) * | 2010-03-10 | 2015-05-13 | アッヴィ・バハマズ・リミテッド | 固体組成物 |
| JP5911476B2 (ja) | 2010-05-26 | 2016-04-27 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヘテロアリール化合物及びその使用方法 |
| MX2012014301A (es) * | 2010-06-07 | 2013-04-29 | Enanta Pharm Inc | Inhibidores macrociclicos de serina proteasa de hepatitis c. |
| NZ608720A (en) | 2010-09-21 | 2015-03-27 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| US20120101032A1 (en) * | 2010-10-22 | 2012-04-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| CN103380132B (zh) * | 2010-12-30 | 2016-08-31 | 益安药业 | 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| CA2822556A1 (en) * | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2802595B1 (en) | 2012-01-11 | 2016-01-06 | AbbVie Inc. | Processes for making hcv protease inhibitors |
| JP2015533124A (ja) | 2012-10-08 | 2015-11-19 | アッヴィ・インコーポレイテッド | Ｈｃｖプロテアーゼ阻害剤を作製するのに有用な化合物 |
| EA025560B1 (ru) | 2012-10-19 | 2017-01-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| US9643999B2 (en) * | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) * | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN111689951A (zh) * | 2020-06-11 | 2020-09-22 | 西北师范大学 | 一种1-苄基-3-烷基喹喔啉-2(1h)-酮的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| JP4352594B2 (ja) * | 2000-03-15 | 2009-10-28 | 三菱マテリアル株式会社 | 酸化物イオン伝導体及びその製造方法並びにこれを用いた燃料電池 |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| JP2007524576A (ja) * | 2003-02-07 | 2007-08-30 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状のｃ型肝炎セリンプロテアーゼ阻害剤 |
| US7173004B2 (en) * | 2003-04-16 | 2007-02-06 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus |
| CA2522561C (en) | 2003-04-18 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors |
| US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| PE20050431A1 (es) * | 2003-09-22 | 2005-07-19 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c |
| BRPI0414814A (pt) * | 2003-09-26 | 2006-11-14 | Schering Corp | inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2546290A1 (en) * | 2003-11-20 | 2005-06-09 | Schering Corporation | Depeptidized inhibitors of hepatitis c virus ns3 protease |
| WO2005058821A1 (en) * | 2003-12-11 | 2005-06-30 | Schering Corporation | Inhibitors of hepatitis c virus ns3/ns4a serine protease |
| ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
| CN101273038A (zh) | 2005-07-29 | 2008-09-24 | 美迪维尔公司 | 丙型肝炎病毒的大环化合物抑制剂 |
| US7741281B2 (en) * | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2007
- 2007-06-25 UY UY30437A patent/UY30437A1/es not_active Application Discontinuation
- 2007-06-25 TW TW096122888A patent/TWI454264B/zh not_active IP Right Cessation
- 2007-06-25 AR ARP070102807A patent/AR061629A1/es unknown
- 2007-06-25 PE PE2007000815A patent/PE20080992A1/es active IP Right Grant
- 2007-06-26 NZ NZ573275A patent/NZ573275A/en unknown
- 2007-06-26 CN CN200780024107.8A patent/CN101478970B/zh active Active
- 2007-06-26 CA CA2654945A patent/CA2654945C/en not_active Expired - Fee Related
- 2007-06-26 JP JP2009518517A patent/JP5520046B2/ja active Active
- 2007-06-26 KR KR1020097001503A patent/KR101505056B1/ko not_active IP Right Cessation
- 2007-06-26 US US11/768,723 patent/US8809264B2/en not_active Expired - Fee Related
- 2007-06-26 MX MX2008016528A patent/MX2008016528A/es active IP Right Grant
- 2007-06-26 US US11/768,712 patent/US8501681B2/en not_active Expired - Fee Related
- 2007-06-26 WO PCT/US2007/072140 patent/WO2008002924A2/en active Application Filing
- 2007-06-26 EP EP07784548A patent/EP2066326A4/en not_active Withdrawn
- 2007-06-26 BR BRPI0714074-6A patent/BRPI0714074A2/pt not_active Application Discontinuation
- 2007-06-26 AU AU2007265157A patent/AU2007265157B2/en active Active
- 2007-06-26 RU RU2009102252/04A patent/RU2475494C2/ru active
-
2008
- 2008-11-25 IL IL195512A patent/IL195512A/en active IP Right Grant
- 2008-12-11 ZA ZA200810519A patent/ZA200810519B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009541491A (ja) | 2009-11-26 |
| US20070299078A1 (en) | 2007-12-27 |
| US8809264B2 (en) | 2014-08-19 |
| WO2008002924A2 (en) | 2008-01-03 |
| KR101505056B1 (ko) | 2015-03-23 |
| TWI454264B (zh) | 2014-10-01 |
| KR20090023732A (ko) | 2009-03-05 |
| IL195512A (en) | 2014-05-28 |
| PE20080992A1 (es) | 2008-08-06 |
| IL195512A0 (en) | 2009-09-01 |
| TW200810777A (en) | 2008-03-01 |
| JP5520046B2 (ja) | 2014-06-11 |
| CN101478970A (zh) | 2009-07-08 |
| BRPI0714074A2 (pt) | 2012-12-18 |
| AU2007265157A1 (en) | 2008-01-03 |
| CA2654945C (en) | 2013-08-06 |
| RU2475494C2 (ru) | 2013-02-20 |
| CA2654945A1 (en) | 2008-01-03 |
| ZA200810519B (en) | 2009-08-26 |
| UY30437A1 (es) | 2008-01-31 |
| RU2009102252A (ru) | 2010-08-10 |
| CN101478970B (zh) | 2014-07-02 |
| WO2008002924A3 (en) | 2008-04-03 |
| US8501681B2 (en) | 2013-08-06 |
| EP2066326A2 (en) | 2009-06-10 |
| AU2007265157B2 (en) | 2013-06-27 |
| EP2066326A4 (en) | 2010-09-29 |
| US20080008681A1 (en) | 2008-01-10 |
| NZ573275A (en) | 2011-12-22 |
| MX2008016528A (es) | 2009-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061629A1 (es) | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas | |
| AR062224A1 (es) | Tetrazolilos macrociclicos como inhibidores de serina proteasa ns3 del virus de hepatitis c y composiciones farmaceuticas que los comprenden. | |
| AR083052A1 (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas | |
| PE20090042A1 (es) | Analogos de ciclopamina | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| AR061238A1 (es) | Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c | |
| AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
| AR079689A1 (es) | Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias. | |
| ECSP077649A (es) | Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| AR055395A1 (es) | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c | |
| AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| AR101106A1 (es) | Inhibidores de tirosina quinasa de bruton | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR084217A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR064304A1 (es) | Formulaciones de ansamicina y sus metodos de uso | |
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| AR070395A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il- amina | |
| CO6220931A2 (es) | Inhibidores de serina proteasas para el tratamiento de infecciones de vhc | |
| PE20121526A1 (es) | Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |